Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Readying To Launch Acid Reflux Med Kapidex Within A Month

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese drug maker looks to dexlansoprazole to help offset loses when Prevacid and anti-diabetic Actos go off patent this year.

You may also be interested in...



New Zealand PHARMAC Proposes Lifting Restrictions On Merck’s Fosamax; Reduces Subsidy For EC Aspirin

PERTH, Australia - New Zealand's Pharmaceutical Management Agency has proposed lifting some of the restrictions on drugs classified for musculoskeletal system therapies, effective March 1, the agency announced Jan. 12

U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin

U.S. FDA has set a new action date of June 26, 2009 for Takeda's dipeptidyl peptidase IV inhibitor alogliptin, after missing the original user fee deadline of Oct. 27, the company announced Dec. 24

Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug

TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said

Related Content

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel